clinical use for almost 70 years, and early on were also used in conjunction with exposure to the measles virus or polio virus. The US regulations that describe functional Ig lot release thus require the demonstration of minimum antibody titers against these two viruses, although the use of vaccines has now dramatically reduced their incidence. The lower clinical importance of these viruses raises the question of whether other virus antibodies might be more informative for patients with immunodeficiency.
STUDY DESIGN AND METHODS:
A literature survey was conducted to identify viruses of potential clinical concern for people with immunodeficiency. The viruses selected have stable seroepidemiology and associated functional antibody assays. As a result, neutralizing antibody titers to human adenovirus 5 (HAdV5), respiratory syncytial virus (RSV) serotypes A and B, and human parainfluenza virus 3 (hPIV3) were determined in Ig lots produced from plasma collected in either the United States or the European Union.
RESULTS:
The virus antibody titers measured were high and consistent among the Ig lots tested. Use of either US-or EU-derived plasma as starting material resulted in equivalent virus antibody titers, with the exception of RSV serotype B, for which a lower titer was seen in EU plasma-derived Ig lots.
CONCLUSION:
With the significant decline in measles virus and polio virus circulation, and even their potential eradication, measurement of antibody titers against other viruses in Ig products may be more informative for functional lot release testing.
S
ince the 1950s, when Colonel Ogden Bruton first infused the γ-globulin fraction of human plasma into a person with an immunodeficiency (primary immunodeficiency; PID), 1 Some of the early regulations around the production of Ig, for example, the criteria for functional lot release testing as defined in the US Code of Federal Regulations (CFR), 3 have not changed since first implementation. At the time, requirements for minimum levels of functionally active antibodies against polio virus and measles virus were perfectly reasonable for demonstrating the biologic activity of Ig lots before release to the market (for comprehensive detail see the contribution by Dorothy E. Scott in this supplement), as, in fact, Ig was used to protect against these viruses. The progressive vaccine-enabled elimination of these two viruses established a very different scenario. The imminent eradication of polio virus will render any use of infectious virus undesirable to prevent reintroduction into humans, 4 and may thus complicate, if not prevent, the determination of functionally active antibody titers against this virus. Progress in elimination of the measles virus has not been as significant, but the wide use of measles virus vaccines, as opposed to earlier infections, that gave rise to higher antibody titers, resulted in a continuous decline of measles virus antibody titers in plasma for fractionation (for further details see the contribution of Toby L. Simon in this supplement). This decline is reflected in individual lots of Ig, 5 an observation similar to the changes reported for hepatitis A virus (HAV) antibodies. 6 Meeting the CFR-required lot release threshold for Ig has thus become increasingly challenging, with the potential loss of Ig lots, that is, a therapeutic in high demand that is derived from the ethically motivated donations of raw material still available in limiting quantities.
To mitigate the concerns around decreasing measles virus antibody titers, and thus potentially failing Ig lot release, measles (re-)vaccination of plasma donors to boost antibody levels has recently been evaluated. However, this resulted in only an approximately twofold increase in antibody titers that returned to baseline within a few months after vaccination-clearly not a long-term sustainable solution. 7 Despite the circulation of both the polio virus and measles virus being in decline and in fact progressing toward eradication, confirmation of functional antibody activity during Ig lot release is still required. Therefore, antibody titers against viruses other than measles virus and polio virus may be more informative for people who use Ig as replacement therapy for immunodeficiencies. Proof of consistent antibody titers against viruses that are of clinical relevance to PIDs would be of interest. Information about the presence of antibodies against emerging viruses might also be relevant, as geographic differences in the epidemiology of a virus result in differential exposure of populations to that virus, which is reflected in the antibody specificities contained in the Ig fractionated from the plasma collected in that given region. For instance, it is intriguing to review the emergence of West Nile virus (WNV) in the United States after 1999, which resulted in the exposure of an entirely naive population, and where the virus has established endemicity with intermittent epidemics since. 8 The increasing cumulative exposure of the US population resulted in growing numbers of WNV antibody-positive individuals and thus plasma donations, and finally in a potent WNV neutralization capacity of US plasma-derived Ig lots, 9,10 the passive transfer of which afforded protection against an otherwise lethal WNV challenge in a susceptible animal model of this flaviviral disease. 9, 11 In Central and Eastern Europe and Northern Asia, the circulation of tickborne encephalitis virus (TBEV) and the widespread use of a vaccine against this Flavivirus, which is closely related to WNV, resulted in significant TBEV neutralization capacity of EU plasma-derived Ig lots, whereas TBEV-specific antibodies were not present in Ig lots fractionated from plasma sourced in the United States, as TBEV is not present in this geography. 12 In fact, the approach of using individual lots of Ig as samples in seroepidemiologic investigations, with each lot of Ig reflective of the serostatus of several thousand plasma donors, did allow for the first identification of WNV circulation in humans in Central Europe. 13 In the study presented here, virus antibody titers in Ig preparations other than to the polio virus and the measles virus were investigated, with the intent of identifying potential future alternatives suitable for functional Ig lot release testing, which may in addition provide relevant information for current Ig users as well as the concerned medical community.
MATERIAL AND METHODS

Choice of alternative virus antibody specificities
A literature-based search for alternative target viruses for use in a functional Ig lot release test was focused around three major criteria that were considered essential to support a long-term solution:
1. Clinical utility, that is, information about the specific virus antibody level, had to be associated ideally with a potential benefit for PID treatment. On the contrary, the virus should be of only minor importance for the general population, and thus an unlikely target for vaccine development, as otherwise long-term phenomena similar to those observed for measles virus and HAV, that is, a vaccine-driven decline in population antibody levels, might be again encountered. 2. Seroprevalence, which would ideally be rather high, and with only minor fluctuations with time and across the major geographic regions for plasma sourcing, that is, the United States and Europe. 3. Virology, that is, the availability of a simple cell culture system to grow and titrate the virus, ideally at low biosafety level (BSL) and with a highly reproducible assay. stocks were characterized by a generally 10-fold titer determination (see below) and confirmation of absence of mycoplasma.
Viruses and cells
Virus infectivity and neutralization assays
Virus infectious titers were determined in tissue culture infective dose 50% (TCID 50 ) assays, using serial half-log sample dilutions that were titrated in eightfold replicates on 96-well plates. After incubation for 7 days in humidified CO 2 incubators at 36 C, wells were scored for virus infection by evidence of a cytopathic effect and infectious virus titers (expressed as log TCID 50 /mL) calculated according to the Poisson distribution and the maximum likelihood method. 15 Neutralizing antibody titers were determined in twofold steps serially diluted Ig lots manufactured from plasma that had been sourced from the United States (n = 24) and from the European Union (n = 8), in commercial lots of Gammagard Liquid (for the US market) and KIOVIG (for the EU market), 10%, triple virally reduced (Shire, Lexington, MA) that were mixed 1:2 with working virus stock adjusted to a 10 3 TCID 50 /mL dose, incubated for 2-3 hours at room temperature and subsequently titrated in 96-well format in eightfold replicates. After incubation for 7 days, cells were evaluated microscopically for the presence of a cytopathic effect and the virus neutralization titer (μNT 50 ), that is, the reciprocal Ig dilution resulting in 50% virus neutralization was determined using the Spearman-Kärber formula. Assays were done in duplicate by two operators on different days. The RSV-specific monoclonal antibody palivizumab (Synagis, AbbVie, Austria) was included in the RSV neutralization assay for comparison.
Data analysis
Statistical differences of virus antibody titers were evaluated by unpaired t test, using GraphPad Prism version 6.07 for Windows (GraphPad Software, California), and results are given as mean AE standard deviation.
RESULTS
Choice of alternative virus antibody specificities
The following viruses were identified as concerns for PIDs by major stakeholders, and knowledge about antibody titers against these in Ig preparations are therefore of potential clinical utility: cytomegalovirus (CMV), HAdV, varicella zoster virus (VZV), Epstein-Barr virus (EBV), enteroviruses (coxsackie virus and echovirus), RSV, hPIV, herpes simplex virus (HSV), rota virus, WNV, HAV, hepatitis B and C viruses (HBV and HCV, respectively), rhino virus, and influenza virus. [16] [17] [18] [19] [20] [21] [22] [23] Of these, VZV, HAV, rhino virus, influenza virus, HBV, HCV, WNV, and rota virus are of importance in the general population, with routine vaccination programs established or vaccines under development. Given that history has demonstrated the complications for Ig-lot release testing associated with changes in population antibody titers driven by the introduction of vaccines, these viruses were excluded from further investigation. The global seroprevalence of the remaining candidates was generally high, with geographic and temporal fluctuations, or both, in prevalence known for viruses for which numerous serotypes exist, such as coxsackie virus or echovirus, [24] [25] [26] which were thus also excluded.
Of the remaining candidates, no simple cell culture system is available for EBV, and different neutralization assay formats exist for CMV, with unclear correlation of results with clinical relevance. 25, 27, 28 HAdV, RSV, and hPIV were thus finally selected for further investigation.
Human adenovirus (HAdV)
Adenovirus infection can be impactful for people with immunodeficiencies, yet in healthy individuals they are not typically associated with significant clinical disease, with the exception of HAdV4 and HAdV7, which have thus far been the only serotypes for which a vaccine was developed. 18 More than 50 HAdV serotypes are known, of which HAdV5 is among the most common, with a fairly constant seroprevalence of 60%-70% in the United States and Europe. 29, 30 HAdV5 is simple to cultivate and titrate, with infectious virus stock titers in the range of 9-10 log TCID 50 /mL achieved within 4 days under BSL2 containment requirements.
High and fairly consistent HAdV5 neutralizing antibody titers were determined in Ig lots that were manufactured from plasma collected in the United States (n = 24) or the European Union (n = 8), which did not differ significantly between the two geographic regions (p = 0.76) (Fig. 1A) . A subanalysis was performed on the US plasma-derived Ig lots distinguished between lots that had been fractionated from source plasma collected by apheresis from typically younger donors (n = 18) and lots manufactured from plasma recovered from whole blood donations collected from an on average advanced age donor group (n = 6). This analysis revealed a statistically significantly higher titer in source plasma-derived Ig lots (p < 0.0001).
Respiratory syncytial virus (RSV)
RSV, which exists in serotypes A and B, occurs worldwide, with an estimated 100% of children in the United States infected by 3 years of age; as immunity wanes over time, reinfection is frequent. 31 Although infection with serotype B remains typically asymptomatic, serotype A can cause more pronounced disease, and more so in the young, the elderly, and immunocompromised individuals. A vaccine is thus in development, and an RSV-neutralizing monoclonal antibody is available for clinical use (Synagis).
RSV was somewhat more difficult to propagate, particularly for serotype A, yet infectious virus stock titers in the range of 4 log TCID 50 /mL were achievable within 7-8 days of culture under BSL2 containment requirements. Ig lots contained consistent levels of RSV-neutralizing antibodies, for both serotype A (Fig. 1B) and serotype B (Fig. 1C) . The observation that, in the same neutralization assay, μNT 50 titers of 1:35,700 and 1:71,500 were obtained for Synagis with serotypes A and B, respectively, correlates well with the higher neutralization titers obtained for the Ig lots with the B serotype RSV (Fig. 1C) . It is tempting to speculate that the generally somewhat higher antibody titers against serotype B versus A may have been influenced by the more difficult to grow and thus likely higher antigen-to-infectivity virus preparation for serotype A.
Although for serotype A the difference of virusneutralizing titers between US and EU plasma-derived IG lots was not significant (p = 0.15), serotype B antibody titers were significantly higher in Ig lots produced from US plasma (p = 0.0028). Differences in antibody titers against either serotype were not significant for source and recovered plasma-derived Ig lots (serotype A: p = 0.38; serotype B: p = 0.22).
Human parainfluenza virus 3 (hPIV3)
hPIV is endemic worldwide, 31 and similar to RSV, first infection occurs early in childhood with frequent reinfections throughout life, which usually result in only mild illness with cold-like symptoms in the general population. In children, the elderly, and persons with PID, hPIV is the cause of severe infections. 32, 33 Of the different serotypes, isolates of serotype 1 and 2 are associated with croup in children, whereas serotype 3 (hPIV3) causes illness with bronchitis and pneumonia. 32, 33 Nearly all children have experienced hPIV3 infection by the age of 5 years.
33
hPIV3 is simple to cultivate and titrate, with infectious virus stock titers in the range of 8 log TCID 50 /mL achieved within 5-7 days under BSL2 containment requirements.
Similar to HAdV5 and RSV, high and consistent hPIV3-neutralizing antibody titers were seen in Ig manufactured from plasma collected in the United States and the European Union, with no significant difference between the two geographic regions (p = 0.88) (Fig. 1D) or between US Ig lots that had been fractionated from source or recovered plasma (p = 0.16).
DISCUSSION
After almost 70 years of clinical use, the importance of Ig for treatment of immunodeficiencies is firmly established, and most visibly illustrated by the WHO designation of Ig as essential medicine, a definition based on their "public health relevance, evidence on efficacy and safety, and comparative cost-effectiveness". 34 Over time, however, efficacy concerns initially considered critical for Ig use, for example, exposure to the measles virus or polio virus, have decreased in importance, with the limited, or almost eliminated, circulation of these viruses in most parts of the world. However, US regulations developed during the early days of Ig use still require the demonstration of minimum antibody titers against these two viruses for functional lot release testing, requirements that are increasingly more difficult to meet and thus have a potentially negative impact on Ig availability. Once the ongoing eradication efforts focused on these two viruses have reached their final goal, the replacement of measles virus and polio virus antibody titers as a functional potency requirement will ultimately be inevitable, since in the absence of these virus antigens, production of the respective antibodies will not be triggered. An evaluation was thus initiated to determine whether other virus antibody tests could equally confirm functional activity for individual lots of Ig during release testing, while at the same time provide more relevant information for the community concerned with immunodeficiencies, and thus eventually replace the current test requirements.
A literature review of virus antibodies, based on 1) potential clinical benefit for the treatment of PID, 2) a stable and geographically similar seroprevalence, and 3) availability of a practical virology test system for quantification of virus antibodies in a quality control setting under low biosafety requirements as selection criteria, revealed antibodies to HAdV5, RSV, and hPIV3 as potentially promising candidates. Virus antibody assays were thus established, and the titers measured in feasibility studies were high and fairly consistent among the Ig lots tested, irrespective of whether they had been manufactured from US or EU plasma. The sole exception to these findings was RSV serotype B, with EU plasma-derived IG lots showing a significantly lower titer, although the reason for this observation could not be identified.
Of interest was the generally different level of neutralization titers for Ig lots as well as for a commercially available monoclonal antibody (Synagis) against RSV serotype A and B viruses. A larger amount of noninfectious virus particles as presumably contained in the more difficult to grow serotype A virus preparation, that is, antigen that can bind virus antibodies without resulting in neutralization of virus infectivity, is a likely cause for this effect. And although the absolute virus neutralization titers determined in the current study were meant to only establish proof-of-concept, with only comparison between different Ig lots as the target, the observation emphasizes the need for characterization of virus stock preparations used in neutralization assays, as well as standardization of results by establishing antibody standard preparations.
HSV, which had also been identified as a potential candidate virus, may be another interesting option to evaluate further in the future.
Beyond their purpose of confirming functional activity for each lot of Ig at release, virus antibody assays initially defined in the CFR were also meant to support medical practice, that is, at the time, to ensure protection against measles virus and polio virus infections. With those two viruses on their way to a presence in textbooks only, information about the neutralization capacity of Ig for other viruses currently in circulation may be more pertinent and informative for Ig treatment.
